We are happy to welcome in our cluster Velabs Therapeutics, dedicated to fast generation of antibodies against target molecules.
Velabs Therapeutics is a spin-out company launched by Europe's most renowned institute for life sciences research, the European Molecular Biology Laboratory (EMBL) and its technology transfer arm EMBLEM Technology Transfer (EMBLEM). The institute has an outstanding track record in instrumentation development and is at the forefront of microfluidics-based screening technology and applications world-wide.
The company’s droplet-based microfluidic screening technology aims at the fast generation of antibodies against target molecules presented on cellular membrane surfaces or as soluble protein.
VELABS has pioneered the use of droplet microfluidics for the fast screening of correctly paired human antibodies that do not just bind to a drug target, but rather modulate its function.
We are looking forward to see your active participation in the network!
You can find here more information about Velabs Therapeutic.